Patricia Dozier
Family · Florence, ALNPI 1588216220
Payments from drug & device makers
Across 226 payments — averaging $18.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$509
- Merck$405
- Pfizer$346
- Amgen$338
- Bayer$306
- Irhythm Technologies, Inc.$304
- plus $2K from 23 others
What the payments were for
- Food & beverage$4,279100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 31 | $509 |
| Merck | 20 | $405 |
| Pfizer | 23 | $346 |
| Amgen | 18 | $338 |
| Bayer | 17 | $306 |
| Irhythm Technologies, Inc. | 11 | $304 |
| Boehringer Ingelheim | 11 | $299 |
| Johnson & Johnson | 12 | $248 |
| Novo Nordisk | 11 | $230 |
| Abbott | 15 | $219 |
| AstraZeneca | 14 | $200 |
| Esperion Therapeutics, Inc. | 8 | $158 |
| E.r. Squibb & Sons, L.L.C. | 3 | $118 |
| Alnylam Pharmaceuticals Inc. | 4 | $72 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $72 |
| Nuwellis, Inc. | 3 | $65 |
| United Therapeutics Corporation | 3 | $61 |
| Sanofi-aventis U.S. LLC | 4 | $61 |
| Chiesi USA, Inc. | 3 | $46 |
| Edwards Lifesciences | 2 | $45 |
| Boston Scientific | 2 | $32 |
| Amarin Pharma, Inc. | 1 | $23 |
| Actelion Pharmaceuticals US, Inc. | 1 | $23 |
| Abiomed | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Lexicon Pharmaceuticals, Inc. | 1 | $15 |
| Medtronic | 1 | $15 |
| Scpharmaceuticals Inc. | 1 | $15 |
| Philips North America LLC | 1 | $14 |
How this compares
$4,279 in reported general payments places this provider in the 85th percentile of 3,415 family providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 240 | $200,188 |
| CamzyosMavacamten | 16 | $135,438 |
| EntrestoSacubitril/Valsartan | 36 | $35,829 |
| Repatha SureclickEvolocumab | 37 | $30,338 |
| XareltoRivaroxaban | 33 | $22,174 |
| FarxigaDapagliflozin Propanediol | 30 | $17,533 |
| JardianceEmpagliflozin | 30 | $16,804 |
| BrilintaTicagrelor | 15 | $12,241 |
| Ranolazine ErRanolazine | 73 | $5,636 |
| Prasugrel Hcl | 17 | $1,697 |
| Metoprolol Succinate | 77 | $1,596 |
| Atorvastatin Calcium | 157 | $1,549 |
| Rosuvastatin Calcium | 85 | $1,525 |
| Terazosin Hcl | 34 | $1,399 |
| Potassium Chloride | 73 | $1,342 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $346 | $200,188240 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $118 | $135,43816 claims |
| AstraZenecaFarxiga, Brilinta | $200 | $29,77445 claims |
| Johnson & JohnsonXarelto | $248 | $22,17433 claims |
| Boehringer IngelheimJardiance | $299 | $16,80430 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,415 family providers in Alabama.
Other family in Florence
- Erica ConleyFlorence$16K
- Crystal KeetonFlorence$14K
- Angela GannFlorence$12K
- Justin WilsonCullman$1.1M
- Leigh Ann ChildressHuntsville$240K
- Molly ReevesAuburn$158K
- Christina CanteyHuntsville$118K
- Leigh LunaMontgomery$69K
- Christopher LovellMobile$64K
- Justin SimpsonTuscaloosa$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.